Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.
FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology
TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC
HIFU Proves Noninferior to Radical Prostatectomy in Localized Prostate Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority